Replies to post #182421 on Biotech Values

[bladerunner1717]

FWIW I agree I overstated my position a little when talking about other bio markers changes effected by statins. I think it is best said that the other biomarker effects of statins (lower CRP, higher HDL, specific LDL types) are gaining more and more credence as other potential, equally plausible, MOA. I.e. There is now a cloud of fog around the concept that LDL is the primary beneficial MOA of statins. And the cardiology community has been badly stung repeatedly by other highly touted bio markers that failed (repeatedly) in trials and is now backing off on all of them. Including LDL. E.g. The change in treatment guidelines in 2012/2013 (which removed HDL targets AND LDL targets largely for these reasons)

I've been taking statins for fifteen years. Even when I began taking them, my personal physician told me that he didn't believe that that the MOA of the statins worked through a LDL lowering mechanism. He thought that lowering CRP was the MOA. He said at the time that most cardiologists in Southern CA thought the same thing. He says all the newer studies have vindicated his hypothesis.

Bladerunner